Brian JG Pereira
CIK 1298146 · Executive Chairman · last filed 2026-08-20
Brian JG Pereira is an Executive Chairman who has filed 56 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing shows the insider sold $1.1M of PROK on Aug 20, 2026. Across all open-market trades the lifetime net is −$20.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $37.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMAG price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE, WA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PROK | Director | 27,052 | $1.39 | $37.5K | -$2.95M | 9 | 2026-08-20 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | — | $27.00 | — | $0 | 8 | 2026-06-11 |
| ABEO | Executive Chairman | — | $4.58 | — | $0 | 1 | 2020-04-17 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | 1,000 | — | — | $444.6K | 14 | 2014-03-06 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | President and CEO | 8,958 | — | — | -$18.01M | 19 | 2011-03-02 |
Recent Filings
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-20 | PROK | Sell (S) | −757,164 | -$1.07M | EDGAR |
| 2026-08-18 | PROK | Notice (144) | −675,235 | -$945.3K | EDGAR |
| 2026-08-18 | PROK | Notice (144) | −81,929 | -$114.0K | EDGAR |
| 2026-08-06 | PROK | Conv (C) | +757,164 | $0 | EDGAR |
| 2026-08-06 | PROK | Conv (C) | +757,164 | $0 | EDGAR |
| 2026-06-11 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-05-29 | PROK | Grant (A) | — | $0 | EDGAR |
| 2025-11-14 | PROK | Sell (S) | −757,162 | -$1.88M | EDGAR |
| 2025-11-12 | PROK | Notice (144) | −675,234 | -$1.82M | EDGAR |
| 2025-11-12 | PROK | Notice (144) | −81,928 | -$221.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.